What insurance covers Zepbound?

No insurer covers Zepbound for everyone: whether your plan pays depends first on whether your employer chose to cover weight-loss drugs at all, then on that plan’s prior authorization rules. As of October 2026, CVS Caremark and Aetna have added Zepbound back to their main commercial drug lists, UnitedHealthcare and Cigna cover it with prior authorization when the plan includes weight-loss drugs, and some Blue Cross Blue Shield plans exclude it.

If you have Medicare Part D, the GLP-1 Bridge can cover the Zepbound KwikPen for $50 a month. If your plan says no, Lilly’s self-pay price starts at $299 a month for the 2.5 mg starting dose (Lilly).

Zepbound coverage by insurer

Coverage can differ even inside one insurer. The rules below are each company’s standard documents on the dates shown; your own plan’s drug list and benefit booklet decide.

CVS Caremark and Zepbound

CVS Caremark manages drug benefits for many employers and health plans, so its choices reach well beyond one insurer. On July 1, 2025, it removed Zepbound and preferred Wegovy on its commercial template formularies. Members who had tried Wegovy without enough weight loss, or with side effects they couldn’t tolerate, could ask for a formulary exception.

That has reversed. On May 28, 2026, CVS Health announced that Caremark would add Zepbound back “as an additional preferred option October 1, 2026,” for plan sponsors that cover weight-management drugs. It also lifted its new-to-market block on Foundayo, Lilly’s daily GLP-1 pill, from June 1, 2026. Lilly’s coverage page notes that some employers reinstated Zepbound earlier.

The catch is that plan sponsors “retain discretion to customize coverage.” If your employer never covered weight-loss drugs, the formulary change adds nothing. Call the number on your card and ask whether Zepbound is on your plan’s list and what prior authorization it needs.

Does Aetna cover Zepbound?

Aetna made the same move. Its July 2026 exclusion list for the Standard Control Plan named Zepbound as not covered, with liraglutide, orlistat, Qsymia and Wegovy as the covered options. Aetna’s updates effective October 1, 2026, add Zepbound to the Standard Control, Advanced Control and Aetna Standard Plan formularies, and move Foundayo from non-preferred to preferred.

A formulary listing still isn’t a promise. Your employer decides whether the plan covers weight-loss drugs, and Aetna applies prior authorization before it pays.

Does UnitedHealthcare cover Zepbound?

Only if your employer chose weight-loss coverage. UnitedHealthcare’s weight-loss prior authorization program, effective October 1, 2026, describes itself as “an optional program” for clients that elect it. Where it applies, Zepbound is approved when:

• It’s used alongside lifestyle changes such as diet, exercise or behavioral support
• Your BMI is 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or sleep apnea

The first approval lasts 6 months. A 12-month renewal needs at least 5% loss of your starting weight; if you’re still stepping up to a maintenance dose, UnitedHealthcare allows one extra 6-month approval. For plans that exclude weight-loss drugs, it sends sleep apnea requests to separate Zepbound criteria.

Does Cigna cover Zepbound?

Yes, with prior authorization, when your plan includes weight-loss drugs. Cigna’s Zepbound coverage policy, effective September 1, 2026, approves an 8-month first course for adults who:

• Have tried behavior change and a reduced-calorie diet for at least 3 months
• Had a BMI of 30 or higher before any GLP-1, or 27 or higher with a condition such as high blood pressure, type 2 diabetes, sleep apnea, knee osteoarthritis or PCOS

To continue for a year, you need to have lost at least 5% of your starting weight. Cigna’s policy also says your plan document wins if the two conflict, so an employer exclusion still applies.

Evernorth, The Cigna Group’s health services division, offers plans two cost caps. Its benefit option limits the Wegovy or Zepbound copay to $200 a month and counts that copay toward your deductible. Express Scripts also said in July 2025 it would add Wegovy and Zepbound to its Patient Assurance Program. That announcement gives the program’s $25 cap, for up to a 34-day supply, for diabetes medicines; it doesn’t state a copay for the weight-loss drugs. Both apply only if your plan signs up.

Does Blue Cross Blue Shield cover Zepbound?

Blue Cross Blue Shield isn’t one insurer. Each regional Blue company sets its own drug rules, and self-funded employers add their own choices. Three examples show the range:

• Blue Cross Blue Shield of Massachusetts excludes Wegovy, Saxenda and Zepbound at plan renewals starting January 1, 2026, and every GLP-1 use except type 2 diabetes. Its FAQ says the exclusion can’t be appealed, though employers with more than 100 employees can buy coverage back.
• Blue Cross Blue Shield of Michigan and Blue Care Network ended GLP-1 weight-loss coverage for fully insured large group members on January 1, 2025, or at a later renewal (provider alert). Self-funded groups could keep it.
• FEP Blue, the Blue plan for federal employees, covers Zepbound with prior approval under its 2026 policy. It asks for a BMI of 30, or 27 with heart disease or a weight-related condition, a weight-management program, and a poor result with at least two oral weight-loss drugs and the plan’s preferred product, unless there’s a medical reason not to. The first approval lasts 6 months, and renewal needs 5% weight loss.

If your Blue plan comes through work, ask HR whether it’s fully insured or self-funded, then check the drug list.

The sleep apnea route

Zepbound carries a boxed warning: tirzepatide caused thyroid C-cell tumors in rats, and it isn’t for people with a personal or family history of medullary thyroid carcinoma or MEN 2 (label). Beyond weight management, it’s FDA-approved to treat moderate to severe obstructive sleep apnea in adults with obesity (FDA, December 20, 2024). Some payers treat that use differently:

• Cigna approves Zepbound for sleep apnea for a year when a sleep study shows an apnea-hypopnea index, or respiratory event index, of 15 or more and your BMI is 30 or higher. Continuing past a year needs at least 10% weight loss and stable symptoms.
• UnitedHealthcare sends sleep apnea requests in plans without weight-loss coverage to separate Zepbound criteria.
• Medicare routes sleep apnea requests to your regular Part D plan, not the Bridge (CMS form).
• State Medicaid programs must cover Zepbound for sleep apnea even when they skip obesity coverage (KFF).

It doesn’t work everywhere: Blue Cross Blue Shield of Massachusetts excludes every GLP-1 use except type 2 diabetes. Our guide to Zepbound for sleep apnea covers the diagnosis side.

How to appeal a Zepbound denial

Read the denial letter first. A denial for missing criteria can often be fixed; a plan exclusion usually can’t.

1. Ask your clinician to resubmit with what was missing: starting BMI, weight-related conditions, sleep study results or proof of a diet program. Lilly’s coverage page links a prior authorization guide and a sample letter of medical necessity.
2. If Zepbound isn’t on your drug list, ask for a formulary exception, especially if a preferred drug didn’t work or caused side effects you couldn’t tolerate.
3. File an internal appeal within 180 days of the denial, with a letter from your clinician (HealthCare.gov). Your state’s Consumer Assistance Program can file it for you.
4. If the plan still says no, request an external review within 4 months. Standard reviews are decided within 45 days and urgent ones within 72 hours, and your insurer must accept the result (HealthCare.gov). External review covers denials that involve medical judgment.

Medicare, Medicaid and TRICARE

• Medicare: The Bridge runs from July 1, 2026, to December 31, 2027, and its form lists the Zepbound KwikPen. Eligible Part D enrollees pay $50 a month. See our Medicare guide.
• Medicaid: Covering GLP-1s for obesity is optional for states, while sleep apnea coverage is required (KFF). See Medicaid GLP-1 coverage.
• TRICARE: Prime and Select enrollees can get weight-loss drugs with prior authorization, and TRICARE For Life beneficiaries can’t (TRICARE). See TRICARE and GLP-1s.

What Zepbound costs with or without coverage

If your commercial plan covers the single-dose pen, Lilly’s savings card can cut the cost to as little as $25 a month, with savings capped at $100 a month and $1,300 a year. The card ends December 31, 2026, and people in government programs can’t use it.

Without coverage, LillyDirect charges $299 a month for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg to 15 mg if you refill within 45 days; a late refill costs $499 at 7.5 mg and $699 at 10 mg to 15 mg (Lilly). Our Zepbound cost guide adds up a full year.

Some online programs take on the insurance paperwork. Among the 26 programs we rank, as of November 2026, Measured runs a benefits check and files prior authorizations for brand-name GLP-1s (membership from $49 a month, not billed to insurance), Found accepts most major insurers for clinician visits, and Sesame’s providers help with prior authorization. Compare them on our lists of GLP-1 programs that help with insurance and Zepbound providers.

The bottom line

Ask two questions before you assume anything: does my plan cover weight-loss drugs, and what does its prior authorization require? CVS Caremark and Aetna formularies now include Zepbound again, but employer exclusions still decide. If weight loss is excluded and you have sleep apnea, ask your clinician whether that route fits you. Talk with a licensed clinician about which drug suits you before you file.